Overall, these findings suggest that EIF3J-AS1 could serve as both a prognostic biomarker and a therapeutic target for glioma, providing new insights into disruption of EIF3J-AS1-FOXG1 interactions as a novel autophagy-modulating strategy for glioma treatment. This evidence concerns the gene EIF3J and glioma.